Double-Antigen Immunoassay for Capripoxvirus Antibody Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for detecting antibodies against Capripoxviruses, such as those causing Lumpy Skin Disease, are not sensitive enough to identify animals that have been infected or vaccinated, especially after several weeks or months, and are not easily standardizable or suitable for large-scale analysis.
Innovation Solution
A double-antigen immunoassay method using a synthetic or recombinant rP32 protein specific to Capripoxviruses, which forms a primary antigen/antibody complex with a conjugate containing a marker, allowing for the detection and quantification of antibodies in biological samples, even after 5 months post-infection or vaccination.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional serological screening methods (viral seroneutralization test, Western blot, indirect ELISA) are used to detect antibodies against Capripoxviruses, then the detection can be performed, but the sensitivity is insufficient to identify animals with low levels of neutralizing antibodies, especially after several weeks or months post-infection or vaccination
Solution Approach 1:
The invention uses a double-antigen ELISA format where the detection system is segmented into two separate antigen components: a capture antigen (e.g., A33 protein) immobilized on the plate and a detection antigen (e.g., B5 protein) conjugated to an enzyme. This segmentation allows for enhanced sensitivity by capturing antibodies through one antigen and detecting them through another, providing signal amplification and improved detection of low antibody levels compared to single-antigen methods.
Solution Approach 2:
The invention changes the detection parameters by using recombinant proteins (A33 and B5) with specific molecular weights and epitopic structures that are highly immunogenic and specific to Capripoxviruses. The use of these recombinant antigens with optimized concentrations and incubation conditions enables detection of antibody levels as low as those present months after vaccination, significantly improving measurement precision.
2Ease of manufacture
If conventional serological methods are used, then antibody detection is possible, but the methods are expensive, difficult to implement, and not easily standardizable for large-scale analysis
Solution Approach 1:
The double-antigen ELISA system is designed to be self-contained with all necessary components provided in a standardized kit format: pre-coated microplates with capture antigen, recombinant detection antigen conjugates, blocking buffers, washing buffers, substrate solutions, and control samples. This self-service design eliminates the need for complex virus manipulation infrastructure and allows laboratories to perform large-scale screenings without requiring specialized virology facilities, significantly improving ease of implementation and standardization.
Solution Approach 2:
The invention replaces the complex mechanical and biological systems of virus culture, purification, and handling required by conventional methods with a simplified biochemical assay using recombinant proteins. Instead of requiring cell culture facilities and live virus manipulation, the system uses stable recombinant antigens that can be stored and handled routinely, making the method suitable for large-scale analysis in diverse laboratory settings.
3Duration of action of stationary object
If vaccination is applied to combat Capripoxvirus spread, then protection is achieved, but monitoring vaccination effectiveness becomes difficult after several weeks or months due to declining antibody levels
Solution Approach 1:
The double-antigen ELISA system is designed with preliminary optimization of antigen selection, concentration, and incubation conditions to maximize sensitivity. The capture and detection antigens are pre-selected based on their high immunogenicity and epitopic diversity, allowing the system to detect antibodies even at very low concentrations that persist months after vaccination. This preliminary optimization enables long-term monitoring of vaccination effectiveness.
Solution Approach 2:
The detection system employs a nested structure where the capture antigen-antibody complex serves as the foundation, and the detection antigen conjugate binds to the captured antibodies, creating a nested antigen-antibody-antigen complex. This nested configuration provides signal amplification and extends the detection window, allowing measurement of antibody levels from early post-vaccination through several months later when antibody titers naturally decline.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method provides high sensitivity and specificity, enabling the detection of antibodies in samples up to 5 months post-vaccination, is easily implementable, and can be automated, making it suitable for large-scale analysis without cross-reactions with other virus families.
Implementation Method 1
Bringing at least one primary antigen into contact with a biological sample suspected of containing an antibody specific to said primary antigen, under conditions allowing the formation of an antigen/antibody complex
Implementation Method 2
Addition of at least one conjugate containing a secondary antigen and a marker under conditions allowing the formation of an antigen/antibody/conjugate complex; Detection of said antigen/antibody/conjugate complex
Data Source
AI summary
The invention relates to a method for the immunological dosing of a specific antibody of an antigen (P32 protein or antigenic fragment thereof) of a virus belonging to the Poxviridae family in a biological sample suspected of having been infected and/or vaccinated against said virus. The invention also relates to the corresponding kit and to the uses thereof, particularly for detecting an infection and/or monitoring the vaccination in animals.